Bedfordshire and Luton Joint Prescribing Committee
Ref: JPC Bulletin 213
Bulletin Date: 16/02/15
Review Date: February 2017
Bulletin 213 Eltrombopag (Revolade®) for the treatment of thrombocytopenia in adult patients with chronic hepatitis C virus infection
Eltrombopag(Revolade) for the treatment of thrombocytopenia in adult patients with chronic hepatitis C virus infection, where degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
The JPC agreed to support the attached East of England Priorities Advisory Committee (EoEPAC) Guidance Statement.
Full details available upon request – contact Medicines Optimisation team